|
IM-MV 19-024_000
|
Stichting Katholieke Universiteit
|
EXPLORE: A Phase II, masked multicentre, randomised study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration
|
16-04-2020
|
Vergunning verleend
|
|
IM-MV 20-001_000
|
UMCG
|
Clinical testing of TX200-TR101, an autologous antigen-specific chimeric antigen receptor (CAR) T regulatory cell therapy.
|
12-05-2020
|
Vergunning verleend
|
|
IM-MV 20-002_000
|
Het Nederlands Kanker Instituut
|
Use of autologous patient-derived T cells enriched from peripheral blood mononuclear cells (PBMCs) and transduced with a gamma-retroviral self-inactivating (SIN) vector expressing a second generation chimeric antigen receptor (CAR) with specificity for the oncofetal antigen Claudin6 (CLDN6) under control of an internal promoter in patients suffering from CLDN6-positive malignancies
|
|
Ontwerpbesluit genomen
|
|
IM-MV 20-003_000
|
AMC
|
Clinical studies with MB‐CART2019.1, a product consisting of ex‐vivo lentiviral transduced T‐cells using a replication‐deficient lentiviral vector
|
|
Ontwerpbesluit genomen
|
|
IM-MV 20-004_000
|
UMCG
|
Clinical studies with MB-CART2019.1, a product consisting of ex-vivo lentiviral transduced T-cells using a replication-deficient lentiviral vector
|
|
Ontwerpbesluit genomen
|
|
IM-MV 20-005_000
|
Erasmus MC
|
Use of autologous patient-derived T cells enriched from peripheral blood mononuclear cells (PBMCs) and transduced with a gamma-retroviral self-inactivating (SIN) vector expressing a second generation chimeric antigen receptor (CAR) with specificity for the oncofetal antigen Claudin6 (CLDN6) under control of an internal promoter in patients suffering from CLDN6-positive malignancies
|
|
Ontwerpbesluit genomen
|
